Araştırma Makalesi
BibTex RIS Kaynak Göster

Akut Yetmezlikte Karaciğer Nakli; Tek Merkez Deneyimi

Yıl 2019, Cilt: 4 Sayı: 4, 519 - 525, 31.12.2019
https://doi.org/10.26453/otjhs.563470

Öz

Akut karaciğer yetmezliği, ilerleyici
karaciğer disfonksiyonudur. Karaciğer nakli, etkin bir tedavi seçeneğidir. Bu
çalışmanın amacı akut karaciğer yetmezliği nedeniyle yapılan canlı vericili karaciğer
nakillerini değerlendirmektir.
 Nisan 2014 ile Nisan 2019 tarihleri arasında,
Medipol Üniversitesi Tıp Fakültesi Hastanesi Organ Nakli Bölümü’nde akut
karaciğer yetmezliği nedeniyle canlı vericili karaciğer nakli yapılan 13 hasta
retrospektif olarak değerlendirildi.
Hastaların
yaş ortalaması 21,1±20,9 yıldı. Hastaların dokuzu (%69,2) kadın ve yedisi
   (%53,8) çocukluk (< 18 yıl) yaş grubunda
idi.
 En sık toksik hepatit nedeniyle (%38,5)
karaciğer nakli yapıldı. Hastaların ortalama takip süresi 35,1±12,2 aydı.
Hastaların beşinde (%38,5) komplikasyon gelişti. Hastalardan dördünde (%30,7)
  mortalite görüldü. Genel sağkalım oranı 1 ve
5 yıllık sırasıyla % 84,7 ve % 69,3 idi.

Akut yetmezlikte yapılan canlı vericili karaciğer nakillerinin başarılı olduğu
görünmektedir.

Destekleyen Kurum

Medipol Üniversitesi

Kaynakça

  • 1.Lee WM, Stravitz RT, Larson AM. Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011.Hepatology. 2012; 55:965-967.
  • 2. O’Grady JG. Liver transplantation for acute liver failure. Best Pract Res Clin Gastroenterol. 2012;26: 27–33.
  • 3. Bernal W, Wendon J. Acute liver failure. N Engl J Med 2013; 369: 2525-2534.
  • 4. Krawczyk M, Grąt M, Barski K, Ligocka J, Antczak A, Kornasiewicz O, et al.1000 liver transplantations at the Department of General, Transplant and Liver Surgery, Medical University of Warsaw analysis of indications and results. Pol Przegl Chir 2012; 84:304-312.
  • 5. Nyckowski P, Skwarek A, Zieniewicz K, Patkowski W, Alsharabi A, Wróblewski T, et al. Orthotopic liver transplantation for fulminant hepatic failure. Transplant Proc 2006;38:219-220.
  • 6.BhaduriB, Mieli Vergani G.Fulminant hepatic failure: pediatric aspects.Semin Liv Dis .1996;16:349-355.
  • 7.Trey C,Dawidson CS.The management of fulminant hepatic failure.Progress in Liver Diseases.1970;3:282-298.
  • 8.Siddiqui MS, Stravitz RT. Intensive care unit management of patientswith liver failure. Clin Liver Dis. 2014;18:957-978.
  • 9. N. Goldaracena, V. N. Spetzler, M. Marquez, N. Selzner, M. S. Cattral, P. D. Greig, et al. Live Donor Liver Transplantation: A Valid Alternative for Critically Ill Patients SufferingFrom Acute Liver Failure. American Journal of Transplantation 2015; 15: 1591–1597.
  • 10. Trocello JM1, Broussolle E, Girardot-Tinant N, Pelosse M, Lachaux A, Lloyd C,et al . Wilson’s disease, 100 years later. Rev Neurol. 2013;169:936-943.
  • 11.Jo WS, Hossain MA, Park SC. Toxicological profiles of poisonous, edible,andmedicinal mushrooms.Mycobiology 2014;42:215–220.
  • 12. Ferreira R, Romãozinho JM, Amaro P, Ferreira M, Sofia C. Assessment of emergency liver transplantation criteriain acute liver failure due to Amanita phalloides. Eur J Gastroenterol Hepatol 2011;23: 1226–1232.
  • 13. Matsunami H, Makuuchi M, Kawasaki S, Ishizone S, Mizusawa Y, Kawarasaki H, et al. Living-related liver transplantation in fulminant hepatic failure. Lancet. 1992; 340:1411–1412.
  • 14. Bernal W, Cross TJ, Auzinger G, Sizer E, Heneghan MA, Bowles M, et al. Outcome after wait-listing for emergency liver transplantation in acute liver failure: a single centre experience. J Hepatol 2009;50: 306-313.
  • 15. Park SJ, Lim YS, Hwang S, Heo NY, Lee HC, Suh DJ, et al. Emergency adult-to-adult living-donor liver transplantation for acute liver failure in a hepatitis B virusendemic area. Hepatology 2010;51: 903-911.
  • 16. Matsui Y, Sugawara Y, Yamashiki N, Kaneko J, Tamura S, Togashi J, et al. Living donor liver transplantation for fulminant hepatic failure. Hepatol Res 2008;38: 987-996.
  • 17. Ikegami T, Taketomi A, Soejima Y, Yoshizumi T, Sanefuji K, Kayashima H, et al. Living donor liver transplantation for acute liver failure: a 10-year experience in a single center. J Am Coll Surg 2008; 206: 412-418.
  • 18.Yamashiki N, Sugawara Y, Tamura S, Nakayama N, Oketani M, Umeshita K, et al. Outcomes after living donor liver transplantation for acute liver failure in Japan: results of a nationwide survey. Liver Transpl. 2012;9: 1069-1077.
  • 19. Germani G, Theocharidou E, Adam R, Karam V, Wendon J, O'Grady J, et al. Liver transplantation for acute liver failure in Europe: outcomes over 20 years from the ELTR database. J Hepatol. 2012;57: 288–296
  • 20. Mehrotra S, Mehta N, Rao PS, Lalwani S, Mangla V, Nundy S. Live donor liver transplantation for acute liver failure: A single center experience. Indian J Gastroenterol. 2018;37 : 25-30.

Liver Transplantations in Acute Failure; A Single Center Experiences

Yıl 2019, Cilt: 4 Sayı: 4, 519 - 525, 31.12.2019
https://doi.org/10.26453/otjhs.563470

Öz

Acute hepatic failure is progressive
liver dysfunction. Liver transplantation is an effective treatment option. The
aim of this study was to evaluate the living donor liver transplantation due to
acute liver failure. Between April 2014 and April 2019 at Medipol University
Medical Faculty Hospital Organ Transplantation Department, 13 patients with
living donor liver transplantations in acute failure was studied
retrospectively. The mean age of the patients was 21.1±20,9 years. Of these
patients, nine (69.2%) were female and seven (53.8%) were children (< 18
years old) . Liver transplantation was the most common cause of toxic hepatitis
(38.5%). The mean follow-up of the period was 35.1±12.2 months. Complications
were seen in five patients (38.5%). Mortality was observed in four patients (30.7%).
Overall survival rate was 84.7% and 69,3% in 1 and 5 years, respectively. Living
donor liver transplantation appears to be successful in acute failure.

Kaynakça

  • 1.Lee WM, Stravitz RT, Larson AM. Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011.Hepatology. 2012; 55:965-967.
  • 2. O’Grady JG. Liver transplantation for acute liver failure. Best Pract Res Clin Gastroenterol. 2012;26: 27–33.
  • 3. Bernal W, Wendon J. Acute liver failure. N Engl J Med 2013; 369: 2525-2534.
  • 4. Krawczyk M, Grąt M, Barski K, Ligocka J, Antczak A, Kornasiewicz O, et al.1000 liver transplantations at the Department of General, Transplant and Liver Surgery, Medical University of Warsaw analysis of indications and results. Pol Przegl Chir 2012; 84:304-312.
  • 5. Nyckowski P, Skwarek A, Zieniewicz K, Patkowski W, Alsharabi A, Wróblewski T, et al. Orthotopic liver transplantation for fulminant hepatic failure. Transplant Proc 2006;38:219-220.
  • 6.BhaduriB, Mieli Vergani G.Fulminant hepatic failure: pediatric aspects.Semin Liv Dis .1996;16:349-355.
  • 7.Trey C,Dawidson CS.The management of fulminant hepatic failure.Progress in Liver Diseases.1970;3:282-298.
  • 8.Siddiqui MS, Stravitz RT. Intensive care unit management of patientswith liver failure. Clin Liver Dis. 2014;18:957-978.
  • 9. N. Goldaracena, V. N. Spetzler, M. Marquez, N. Selzner, M. S. Cattral, P. D. Greig, et al. Live Donor Liver Transplantation: A Valid Alternative for Critically Ill Patients SufferingFrom Acute Liver Failure. American Journal of Transplantation 2015; 15: 1591–1597.
  • 10. Trocello JM1, Broussolle E, Girardot-Tinant N, Pelosse M, Lachaux A, Lloyd C,et al . Wilson’s disease, 100 years later. Rev Neurol. 2013;169:936-943.
  • 11.Jo WS, Hossain MA, Park SC. Toxicological profiles of poisonous, edible,andmedicinal mushrooms.Mycobiology 2014;42:215–220.
  • 12. Ferreira R, Romãozinho JM, Amaro P, Ferreira M, Sofia C. Assessment of emergency liver transplantation criteriain acute liver failure due to Amanita phalloides. Eur J Gastroenterol Hepatol 2011;23: 1226–1232.
  • 13. Matsunami H, Makuuchi M, Kawasaki S, Ishizone S, Mizusawa Y, Kawarasaki H, et al. Living-related liver transplantation in fulminant hepatic failure. Lancet. 1992; 340:1411–1412.
  • 14. Bernal W, Cross TJ, Auzinger G, Sizer E, Heneghan MA, Bowles M, et al. Outcome after wait-listing for emergency liver transplantation in acute liver failure: a single centre experience. J Hepatol 2009;50: 306-313.
  • 15. Park SJ, Lim YS, Hwang S, Heo NY, Lee HC, Suh DJ, et al. Emergency adult-to-adult living-donor liver transplantation for acute liver failure in a hepatitis B virusendemic area. Hepatology 2010;51: 903-911.
  • 16. Matsui Y, Sugawara Y, Yamashiki N, Kaneko J, Tamura S, Togashi J, et al. Living donor liver transplantation for fulminant hepatic failure. Hepatol Res 2008;38: 987-996.
  • 17. Ikegami T, Taketomi A, Soejima Y, Yoshizumi T, Sanefuji K, Kayashima H, et al. Living donor liver transplantation for acute liver failure: a 10-year experience in a single center. J Am Coll Surg 2008; 206: 412-418.
  • 18.Yamashiki N, Sugawara Y, Tamura S, Nakayama N, Oketani M, Umeshita K, et al. Outcomes after living donor liver transplantation for acute liver failure in Japan: results of a nationwide survey. Liver Transpl. 2012;9: 1069-1077.
  • 19. Germani G, Theocharidou E, Adam R, Karam V, Wendon J, O'Grady J, et al. Liver transplantation for acute liver failure in Europe: outcomes over 20 years from the ELTR database. J Hepatol. 2012;57: 288–296
  • 20. Mehrotra S, Mehta N, Rao PS, Lalwani S, Mangla V, Nundy S. Live donor liver transplantation for acute liver failure: A single center experience. Indian J Gastroenterol. 2018;37 : 25-30.
Toplam 20 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Konular Sağlık Kurumları Yönetimi
Bölüm Araştırma Makalesi
Yazarlar

Gokhan Ertugrul 0000-0002-8351-4220

Tumay Yanaral Bu kişi benim 0000-0003-3917-8183

Yayımlanma Tarihi 31 Aralık 2019
Gönderilme Tarihi 12 Mayıs 2019
Kabul Tarihi 29 Ağustos 2019
Yayımlandığı Sayı Yıl 2019 Cilt: 4 Sayı: 4

Kaynak Göster

AMA Ertugrul G, Yanaral T. Akut Yetmezlikte Karaciğer Nakli; Tek Merkez Deneyimi. OTSBD. Aralık 2019;4(4):519-525. doi:10.26453/otjhs.563470

Creative Commons Lisansı

Online Türk Sağlık Bilimleri Dergisi Creative Commons Atıf-GayriTicari 4.0 Uluslararası Lisansı ile lisanslanmıştır.

Bu, Creative Commons Atıf Lisansı (CC BY-NC 4.0) şartları altında dağıtılan açık erişimli bir dergidir. Orijinal yazar(lar) veya lisans verenin adı ve bu dergideki orijinal yayının kabul görmüş akademik uygulamaya uygun olarak atıfta bulunulması koşuluyla, diğer forumlarda kullanılması, dağıtılması veya çoğaltılmasına izin verilir. Bu şartlara uymayan hiçbir kullanım, dağıtım veya çoğaltmaya izin verilmez.

Makale gönderme süreçleri ve "Telif Hakkı Devir Formu" hakkında yardım almak için tıklayınız.